233 results about "Radio isotopes" patented technology

A complex of proton accelerators, includes the following functionally interconnected components: a proton source, a cyclotron, at least one target, located either internally or externally to the cyclotron, a medium energy beam transport magnetic channel, a radiofrequency linear accelerator, a high energy beam transport channel towards an area dedicated to the irradiation of tumors with proton beams, as well as a modular system for supplying radio frequency power capable of feeding, independently two or more accelerating modules of the linac. An integrated computerized system controls the complex of accelerators so to carry out, either in alternation or simultaneously, both the production of radioisotopes—for medical, industrial and therapeutical purposes—and the therapeutical irradiation of, even deep seated tumors. The complex of accelerators produces proton beams which, applying the recently developed ‘spot scanning’ technique, are more suited for the tumor irradiation than the ones produced by cyclotrons and synchrotrons.

A brachytherapy seed comprising (a) carrier-free ¹⁰³Pd isotope, (b) a substrate for the carrier-free ¹⁰³Pd radioisotope, and (c) a casing for encapsulating the carrier-free ¹⁰³Pd-laden substrate, is disclosed.

The present application relates to novel excitable particles which can be used in the health sector. It more particularly relates to particles which can generate electrons and/or high energy photon when excited by ionizing radiations such as X- Rays, γ-Rays, radioactive isotope and/or electron beams, and to the uses thereof in health, in particular in human health. The inventive particles are made of an inorganic material comprising oxygen, in particular an oxide, said material having an adequate density, and can be activated in vitro, ex vivo, or in vivo, by controllable external excitation, in order to disturb, alter or destroy target cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or medical device compositions containing same.

The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., ¹⁸F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.

The invention relates to a method for production of a radio-isotope (4) from a target (3), containing a precursor (1) of said radio-isotope (4), using a beam of accelerated particles, comprising the following method steps: preparation of a target (3), containing the precursor (1) of the radioisotope (4), irradiation of said target (3) within an irradiation chamber (10) with a beam of accelerated particles in order to induce the transmutation of the precursor (1) into the radio-isotope (4), heating said target (3) in order to bring about the efflux of the radio-isotope (4) from the target (3), collection of said radio-isotope (4), extracted as a gas and condensation of said radio-isotope (4) into a solid or liquid. The invention further relates to a device for carrying out the above method and use of the device and method for the production of palladium 103 from rhodium 103.

A system for radioisotope production uses fast-neutron-caused fission of depleted or naturally occurring uranium targets in an irradiation chamber. Fast fission can be enhanced by having neutrons encountering the target undergo scattering or reflection to increase each neutron's probability of causing fission (m, f) reactions in U-238. The U-238 can be deployed as layers sandwiched between layers of neutron-reflecting material, or as rods surrounded by neutron-reflecting material.

The invention relates to a large-scale preparation method of high stability caesium removing adsorbent, a product of the preparation method and application of the product, in particular to transitionmetal-stabilized ferrocyanide adsorbent supported by particulate inorganic oxide or activated carbon. The transition metal-stabilized ferrocyanide adsorbent comprises a particulate inorganic oxide carrier or a particulate activated carbon carrier, a transition metal-stabilized ferrocyanide layer which coats the inorganic oxide carrier or activated carbon carrier and a polymer material layer coating the transition metal-stabilized ferrocyanide layer. The adsorbent has high crushing strength and a low ion leaching rate. The invention also relates to the preparation method of the adsorbent and the application of the adsorbent in removal of radioisotope Cs ions, stable-isotope Cs ions, radioisotope Rb ions and stable-isotopic Rb ions.

The present invention refers to a method of treating a cancerous or non-cancerous skin lesion of a subject, e.g. a human patient, by epidermal radioisotope therapy, a specialized type of brachytherapy, comprising the steps of (a) defining and marking an area of skin to be treated; (b) covering said area with a protective layer, e.g. a protective film or foil; (c) applying a tailor-made radioactive source by applying a layer of a radioactive source material on said protective layer, such that said area is covered by said material while any area not to be treated is spared; and (d) removing the radioactive source after a predetermined time period of irradiation.

Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

The invention provides a method using accelerators to produce radio-isotopes in high quantities. The method comprises: supplying a “core” of low-enrichment fissile material arranged in a spherical array of LEU combined with water moderator. The array is surrounded by substrates which serve as multipliers and moderators as well as neutron shielding substrates. A flux of neutrons enters the low-enrichment fissile material and causes fissions therein for a time sufficient to generate desired quantities of isotopes from the fissile material. The radio-isotopes are extracted from said fissile material by chemical processing or other means.

In accordance with the present invention, a system and method is provided for producing a safely disposable end product from waste matter containing undesirable materials, such as infectious, biohazardous, hazardous, or radioactive elements. The method comprises the steps of providing a highly basic solvent, immersing the waste matter containing the undesirable materials within the highly basic solvent, and heating the solvent. The waste matter containing the undesirable materials is allowed to remain within the solvent until digested, thereby forming a solution void of any infectious or biohazardous elements and/or containing a concentration of radioisotope below the maximum permissible concentration (MPC) for release to a sanitary sewer as defined in applicable federal regulations. The invention further provides a system for producing a safely disposable end product void of any infectious or biohazardous elements and/or containing only a concentration of radioisotope below the MPC for release to a sanitary sewer as defined in applicable federal regulations from waste matter containing such materials. The system comprises a tank or vessel capable of containing a highly basic solvent during a closed digestion reaction, heating means for heating the solvent within the vessel, filtering means, and means for removing the post-digestion aqueous solution and solid waste materials from within the vessel. The post-digestion product in both aqueous and solid form can then by disposed of by conventional means.

This invention proposes a robotic applicator device to be deployed internally to a patient having a capsule (also referred to as a cassette) and aperture with a means of alternately occluding and exposing a radioactive source through the aperture. The capsule and aperture will be integrated with a surgical robot to create a robotic IORT (intra-operative radiation therapy) applicator device as more fully described below. The capsule, radiation source, and IORT applicator arm would be integrated to enable a physician, physicist or technician to interactively internally view and select tissue for exposure to ionizing radiation in sufficient quantities to deliver therapeutic radiation doses to tissue. Via the robotic manipulation device, the physician and physicist would remotely apply radiation to not only the tissue to be exposed, but also control the length of time of the exposure. Control means would be added to identify and calculate margin and depth of tissue to be treated and the proper radiation source or radioactive isotope (which can be any particle emitter, including neutron, x-ray, alpha, beta or gamma emitter) to obtain the desired therapeutic effects. The invention enables stereotactical surgery and close confines radiation therapy adjacent to radiosensitive tissue.

The present invention provides an α-particle-emitting radioisotope chelation complex comprising ²²⁵Actinium (²²⁵Ac) and 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′,N′,N′,N′-hexaacetic acid (HEHA) (²²⁵Ac-HEHA). Also provided is a bifunctional HEHA, and a bifunctional ²²⁵Ac-HEHA. The bifunctional HEHA and the bifunctional ²²⁵Ac-HEHA can be conjugated to a targeting agent. In view of the above, the present invention provides a method of making HEHA and methods of making a bifunctional HEHA, including a conjugate thereof. Also provided are a method of treating disease, a method of treating cancer, a method of decontaminating a sample from ²²⁵Ac, a method of decontaminating a person who has been externally contaminated with ²²⁵Ac, and a method of detoxifying a person who has internalized ²²⁵Ac.

The invention provides a medical isotope generation method and device based on a laser wake-field accelerator. Interaction between super-strong and super-short lasers and plasma is utilized to generate a strong flow relativity electron beam. The electron beam is utilized to irradiate a high atomic number target to generate high-flow-strength bremsstrahlung gamma light. The bremsstrahlung gamma light bombards an interested object target to induce a ([gamma], xn+yp) photonuclear reaction or a ([gamma], [gamma]') optical excitation reaction, and object isotopes including gamma rays, electrons, positive electrons and [alpha] particle emitters are generated. By adopting the method provided by the invention, radio isotopes higher in activity are generated, and the cost is relatively low; in addition, the device provided by the invention is compact and convenient to carry, and the device is capable of being placed near a large-sized medical mechanism to be better applied to and serve radiation diagnosis, targeting treatment and other medical applications.

The method shows how to violate predictions of quantum mechanics for matter. For light, the method has been disclosed in patent application Photon Violation Spectroscopy. The methods are different in specifying different methods for light and matter. For matter, the method typically uses the single 5.5 MeV alpha (He++) emitted from the radioisotope Americium-241 in spontaneous decay, a thin gold foil beam splitter, and two surface barrier alpha detectors. The detectors deliver a characteristic electrical pulse with amplitude proportional to matter wave energy. A circuit reads the coincidence rate and singles rates of pulses from the two detectors. Quantum mechanics predicts that the particle would go one way or the other at the beam splitter, and coincident detections of pulses characteristic of such a particle would occur only at an easily calculated chance rate. However, the method at hand shows such characteristic pulses occur in coincidence at a rate greatly exceeding chance. By exceeding chance the method demonstrates surpassing a binding energy threshold and predictions of quantum mechanics. The degree above chance is a new measure in fundamental physics and is usable as a material science probe of the beam splitter. An apparatus specially designed to test for the absence of true coincidences and then perform a beam splitting test to show split-beam coincidences becomes useful in applying the method of Particle Violation Spectroscopy to material science. Fundamental discoveries in physics have been made with this method; therefore it is a method of discovery in physics.